
FDA Sets Goal Date for Antipsychotic Drug, Bysanti
Vanda Pharmaceuticals Inc. announced that a New Drug Application for Bysanti (milsaperidone), for the treatment of acute bipolar I disorder and schizophrenia, has been accepted by the FDA, according to a news release published yesterday. A Prescription …